SAN JOSE, Calif., Feb. 7, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that its presentation titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," has been accepted for presentation at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations in Montreal, Quebec, Canada.  Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for ITUS' liquid biopsy technology.

The presentation will focus on ITUS' proprietary Cchek™ platform which utilizes immuno-profiling via Flow Cytometry and Artificial Intelligence to enable the detection of solid tumors from a blood sample.

"The idea of finding cancer in a tube of blood is a very intriguing concept, that has generated tremendous interest from the scientific and investment community.  ITUS is at the forefront of research in this field, and we are pleased to be presenting our work at this prestigious Keystone Symposium.  As we continue to publicize our progress and eventually publish our data, we hope to increase the profile of our research program in this field," stated Dr. Amit Kumar, President and CEO of ITUS Corporation.

The symposium will be held on March 23-27, 2018, and will be attended by experts in the field of immunotherapy from across the world.  All abstracts can be viewed by registered attendees beginning February 23, 2018.  To receive a copy of the presentation, please email your request to Keystone-2018@ITUScorp.com after March 24, 2018 and include your name, title, and contact information.

Keystone Symposia on Molecular and Cellular Biology
Keystone Symposia on Molecular and Cellular Biology (www.keystonesymposia.org) is a 501(c)(3) nonprofit organization headquartered in Silverthorne, Colorado, USA that convenes open, peer-reviewed conferences across a broad range of the life sciences.  Scientific content for each conference is organized by volunteer scientists who are experts in their respective fields and who also select program speakers, with guidelines from Keystone Symposia to encourage fresh and diverse participation.  The conference Cancer Immunotherapy: Combinations (www.keystonesymposia.org/18C5) will specifically cover the most critical topics regarding how patients with cancer will receive immunotherapy as part of their treatment regimen.  This meeting is also aimed to help address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical.

ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek^TM platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy.  Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™

View original content with multimedia:http://www.prnewswire.com/news-releases/itus-will-present-artificial-intelligence-powered-early-cancer-detection-technology-at-the-keystone-symposia-conference---cancer-immunotherapy-combinations-300594776.html

SOURCE ITUS Corporation